{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:01:07Z","timestamp":1786114867185,"version":"build-2736575974"},"reference-count":135,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473449"],"award-info":[{"award-number":["82473449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503885"],"award-info":[{"award-number":["82503885"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274296"],"award-info":[{"award-number":["82274296"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012465","name":"Dalian Medical University","doi-asserted-by":"publisher","award":["JHCZ2023009"],"award-info":[{"award-number":["JHCZ2023009"]}],"id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012465","name":"Dalian Medical University","doi-asserted-by":"publisher","award":["2022DXDL03"],"award-info":[{"award-number":["2022DXDL03"]}],"id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002979","name":"Dalian Institute of Chemical Physics, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2025-BS-0689"],"award-info":[{"award-number":["2025-BS-0689"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbcan.2026.189649","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:28:25Z","timestamp":1782862105000},"page":"189649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer"],"prefix":"10.1016","volume":"1881","author":[{"given":"Lanxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuowei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189649_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189649_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0015","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bbcan.2026.189649_bb0020","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.23.02505","article-title":"Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update","volume":"42","author":"Loibl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103938","article-title":"Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06\/NCCTG N063D (Alliance)]","volume":"9","author":"de Azambuja","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189649_bb0030","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis","volume":"26","author":"Villacampa","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis","volume":"10","author":"Benitez Fuentes","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0045","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0055","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189649_bb0065","volume":"43","author":"Tolaney","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0070","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","author":"Tolaney","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0075","first-page":"6","article-title":"DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer","author":"Li","year":"2025","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0080","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","article-title":"Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2\u2013positive advanced breast cancer: final results of NCIC CTG MA.31","volume":"33","author":"Gelmon","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0085","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-022-06775-1","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study","volume":"197","author":"Xu","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bbcan.2026.189649_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2\u2013positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0100","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE","volume":"125","author":"Perez","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0105","series-title":"NCCN Clinical Practical Guidelines in Oncology Breast Cancer","author":"National Comprehensive Cancer Network","year":"2026"},{"key":"10.1016\/j.bbcan.2026.189649_bb0110","author":"Gennari"},{"key":"10.1016\/j.bbcan.2026.189649_bb0115","series-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Breast Cancer, 2025 Update","author":"The Chinese Society of Clinical Oncology","year":"2026"},{"key":"10.1016\/j.bbcan.2026.189649_bb0120","first-page":"6","article-title":"Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2. Translational","author":"Li","year":"2025","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s44178-022-00007-8","article-title":"CACA guidelines for holistic integrative management of breast cancer","volume":"1","author":"Wu","year":"2022","journal-title":"Holist Integr Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0130","series-title":"Breast Cancer Clinical Practice Guidelines and Standards, Version 2025","author":"The Chinese Society of Clinical Oncology, The Chinese Society of Clinical Oncology","year":"2026"},{"key":"10.1016\/j.bbcan.2026.189649_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076065","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.bbcan.2026.189649_bb0140","article-title":"Abstract GS1-03: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial","volume":"31","author":"Xu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.bbcan.2026.189649_bb0150","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","article-title":"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer","volume":"24","author":"Robert","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"Valero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0160","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdt543","article-title":"Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer","volume":"25","author":"Baselga","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0165","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdz061","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","volume":"30","author":"Bachelot","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0175","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO-24-01888","article-title":"Trastuzumab-pertuzumab plus eribulin or taxane as first-line chemotherapy for human epidermal growth factor 2-positive locally advanced\/metastatic breast cancer: the randomized noninferiority phase III EMERALD trial","volume":"43","author":"Yamashita","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0180","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0185","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/13543784.2020.1792443","article-title":"Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer","volume":"29","author":"Bartsch","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bbcan.2026.189649_bb0190","series-title":"FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer","year":"2025"},{"key":"10.1016\/j.bbcan.2026.189649_bb0195","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.1009","article-title":"DESTINY-Breast07: dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC","volume":"42","author":"Andre","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10549-020-05728-w","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study","volume":"182","author":"Xu","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bbcan.2026.189649_bb0210","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-21-3435","article-title":"Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002)","volume":"28","author":"Hua","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0215","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-RF3-04","article-title":"Abstract RF3-04: NRG-BR004: a randomized, double-blind, phase III trial of taxane\/trastuzumab\/pertuzumab with atezolizumab or placebo in first-line HER2-positive metastatic breast cancer","volume":"31","author":"Valero","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa2511218","article-title":"Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer","volume":"394","author":"Metzger","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0225","series-title":"2024 San Antonio Breast Cancer Symposium n.d.;Abstract P2-03-20 (SESS-18111)","author":"Metzger","year":"2024"},{"key":"10.1016\/j.bbcan.2026.189649_bb0230","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-25-02600","article-title":"HER2CLIMB-05: a Phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer","volume":"44","author":"Dieras","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0235","series-title":"A Phase III Multicenter, Randomized, Open-label, Active-Controlled Study of SHR-A1811 With or Without Pertuzumab Versus Trastuzumab, Pertuzumab and Docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer","author":"Jiangsu HengRui Medicine Co., Ltd","year":"2025"},{"key":"10.1016\/j.bbcan.2026.189649_bb0240","series-title":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","author":"Sichuan Baili Pharmaceutical Co., Ltd.","year":"2025"},{"key":"10.1016\/j.bbcan.2026.189649_bb0245","author":"Shanghai JMT-Bio Inc","year":"2025"},{"key":"10.1016\/j.bbcan.2026.189649_bb0250","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1186\/s12885-024-12179-9","volume":"24","author":"Kuemmel","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1124","article-title":"INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC)","volume":"42","author":"Swain","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","article-title":"Current and future immunotherapy for breast cancer","volume":"17","author":"Heater","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0270","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/cancers12030636","article-title":"Crosstalk between HER2 and PD-1\/PD-L1 in breast cancer: from clinical applications to mathematical models","volume":"12","author":"Padmanabhan","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189649_bb0275","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14737140.2021.1894932","article-title":"Immunotherapy as a partner for HER2-directed therapies","volume":"21","author":"Clifton","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bbcan.2026.189649_bb0280","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bbrc.2018.02.092","article-title":"Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine","volume":"497","author":"Zhang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bbcan.2026.189649_bb0285","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0295","series-title":"TUKYSATM (Tucatinib) Tablets, for Oral Use","author":"U.S. FOOD And DRUG Administration","year":"2020"},{"key":"10.1016\/j.bbcan.2026.189649_bb0300","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bbcan.2026.189649_bb0305","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.bbcan.2026.189649_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102761","article-title":"The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer","volume":"128","author":"Boscolo Bielo","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbcan.2026.189649_bb0315","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0320","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor\u2013positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0325","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1078-0432.CCR-22-1092","article-title":"Pertuzumab, trastuzumab, and an aromatase inhibitor for HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer: PERTAIN final analysis","volume":"29","author":"Arpino","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0330","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2017.76.7863","volume":"36","author":"Rimawi","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0335","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"45","key":"10.1016\/j.bbcan.2026.189649_bb0340","first-page":"1003","article-title":"Consensus on the clinical use of CDK4\/6 inhibitors for the treatment of hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer (2023 edition)","author":"Breast Cancer Expert Committee of National Tumor Quality Control Center;, Professional Committee on Clinical Research of Tumor Drugs, Chinese Anti-Cancer Association","year":"2023","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.bbcan.2026.189649_bb0345","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1634\/theoncologist.2012-0414","article-title":"First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER","volume":"18","author":"Tripathy","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189649_bb0350","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1093\/oncolo\/oyad137","article-title":"Real-world impact of adjuvant anti-HER2 treatment on characteristics and outcomes of women with HER2-positive metastatic breast cancer in the ESME program","volume":"28","author":"Le Du","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189649_bb0355","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1634\/theoncologist.2019-0446","article-title":"De novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry","volume":"25","author":"Tripathy","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189649_bb0360","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0365","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.bbcan.2026.189649_bb0370","first-page":"00180","article-title":"Characteristics, treatment patterns and clinical outcomes of women with maghreb origin and diagnosis of breast cancer: a single-center, retrospective cohort study","author":"Dauccia","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13058-023-01761-x","article-title":"Prognostic value of baseline neutrophil\/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial","volume":"26","author":"Ding","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0380","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1038\/bjc.2014.174","article-title":"Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER","volume":"110","author":"Yardley","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0385","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1186\/1471-2407-14-806","article-title":"Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer \u2013 results from the HER-OS patient registry","volume":"14","author":"Witzel","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0390","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41416-021-01676-4","article-title":"No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer","volume":"126","author":"Veitch","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0395","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1634\/theoncologist.2018-0213","article-title":"Long-term survival of De Novo Stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy","volume":"24","author":"Wong","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189649_bb0400","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10549-016-3933-6","article-title":"Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer","volume":"159","author":"Harano","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bbcan.2026.189649_bb0405","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3389\/fonc.2019.00789","article-title":"Predictors of long-term disease control and survival for HER2-positive advanced breast cancer patients treated with pertuzumab, trastuzumab, and docetaxel","volume":"9","author":"Hopkins","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120513","article-title":"Advances in prognostic and predictive biomarkers for breast cancer: integrating multigene assays, hormone receptors, and emerging circulating biomarkers","volume":"578","author":"Mondal","year":"2026","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.bbcan.2026.189649_bb0415","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/ijc.30276","article-title":"Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician\u2019s choice in previously treated HER2-positive advanced breast cancer","volume":"139","author":"Kim","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0420","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-15-2499","article-title":"Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer","volume":"22","author":"Baselga","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0425","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0430","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0435","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0440","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.breast.2020.11.006","article-title":"Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer","volume":"55","author":"Liu","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.bbcan.2026.189649_bb0445","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189649_bb0450","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189649_bb0455","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.2147\/OTT.S108419","article-title":"The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis","volume":"9","author":"Wei","year":"2016","journal-title":"OTT"},{"key":"10.1016\/j.bbcan.2026.189649_bb0460","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12967-022-03421-8","article-title":"Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients","volume":"20","author":"Liao","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0465","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.34085","article-title":"The validity of progression-free survival 2 as a surrogate trial end point for overall survival","volume":"128","author":"Woodford","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0470","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104894","article-title":"322P Human epidermal growth factor receptor 2 (HER2)-directed therapies administered after trastuzumab deruxtecan (T-DXd) remain effective in patients (pts) with metastatic breast cancer (mBC): exploratory analysis from DESTINY-Breast02 and -03","volume":"10","author":"Fasching","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189649_bb0480","doi-asserted-by":"crossref","first-page":"oyaf277","DOI":"10.1093\/oncolo\/oyaf277","article-title":"Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study","volume":"30","author":"Liu","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189649_bb0485","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35590","article-title":"Global disparities in cancer care: Bridging the gap in affordability and access to medications between high and low-income countries","volume":"131","author":"Tfayli","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.vhri.2025.101523","article-title":"Economic evaluation and budget impact of biosimilar trastuzumab for HER2-positive metastatic breast cancer in thailand: policy implications for access and affordability","volume":"53","author":"Lochid-amnuay","year":"2026","journal-title":"Value Health Regional Issues"},{"key":"10.1016\/j.bbcan.2026.189649_bb0500","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.21037\/atm-21-3734","article-title":"Clinical diagnosis and treatment of breast cancer with brain metastases and establishment of a prognostic model: a 10-year, single-center, real-world study of 559 cases","volume":"9","author":"Niu","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0505","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-GS01-10","article-title":"Abstract GS01-10: HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0510","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0515","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s44178-023-00053-w","article-title":"Current landscape and challenges ahead of immuno-molecular mechanism and immunotherapy strategy of brain metastases","volume":"2","author":"Guo","year":"2023","journal-title":"Holist Integr Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0520","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody\u2013drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbcan.2026.189649_bb0525","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0530","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0535","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40487-021-00178-w","article-title":"Management of diarrhea in patients with HER2-positive breast cancer treated with neratinib: a case series and summary of the literature","volume":"10","author":"Kruse","year":"2022","journal-title":"Oncol Ther"},{"key":"10.1016\/j.bbcan.2026.189649_bb0540","first-page":"1","article-title":"Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study","author":"Yan","year":"2020","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189649_bb0550","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0555","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbcan.2026.189649_bb0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026760","article-title":"Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib","volume":"6","author":"Kancha","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189649_bb0565","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbcan.2026.189649_bb0570","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1158\/1078-0432.CCR-10-0410","article-title":"Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients","volume":"16","author":"Sperinde","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0575","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0580","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189649_bb0585","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA -mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0590","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbcan.2026.189649_bb0595","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","article-title":"Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189649_bb0600","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06109-7","article-title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+and androgen receptor-positive metastatic or locally advanced breast cancer","volume":"187","author":"Wardley","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bbcan.2026.189649_bb0605","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbcan.2026.189649_bb0610","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti\u2013ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti\u2013PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbcan.2026.189649_bb0615","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-20-0844","article-title":"Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial","volume":"26","author":"Ciruelos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0620","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.22.01063","article-title":"Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update","volume":"40","author":"Henry","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0625","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0630","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of Circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0635","first-page":"4","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","author":"Forshew","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbcan.2026.189649_bb0640","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-11-2696","article-title":"Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood","volume":"18","author":"Higgins","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0645","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1011","article-title":"Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)","volume":"43","author":"Razavi","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0650","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO2-20-01","article-title":"Abstract PO2-20-01: the STOP-HER2 trial: a phase 2 study of stopping trastuzumab - outcomes in patients with HER2+ metastatic breast cancer (TBCRC 062)","volume":"84","author":"Parsons","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111298","article-title":"Circulating tumor cell-blood cell crosstalk: biology and clinical relevance","volume":"40","author":"Pereira-Veiga","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.bbcan.2026.189649_bb0660","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41392-024-01938-6","article-title":"Circulating tumor cells: from new biological insights to clinical practice","volume":"9","author":"Gu","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bbcan.2026.189649_bb0665","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-24-0535","article-title":"Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA","volume":"30","author":"Zhang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbcan.2026.189649_bb0670","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.stem.2025.05.007","article-title":"Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy","volume":"32","author":"Hosking","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbcan.2026.189649_bb0675","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2660","article-title":"A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors","volume":"39","author":"Bauml","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.bbcan.2026.189649_bb0680","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:30:45Z","timestamp":1785969045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":135,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0304419X26001216"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189649","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189649"}}